Trial Profile
A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jul 2012
Price :
$35
*
At a glance
- Drugs Elvitegravir (Primary) ; Antiretrovirals; Ritonavir
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 31 Jul 2011 New trial record